Innoviva, Inc. (INVA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Innoviva reported revenue of $411.3M, up 14.7% from $358.7M the year before. Net income was $271.2M (a 65.9% net margin), or $3.30 per diluted share. Gross margin was 74.8% and operating margin was 39.8%. Operating activities generated $196.9M of cash, leaving $195.8M of free cash flow. At fiscal year end, Innoviva held $1.64B in total assets against $462.3M in total liabilities, including $550.9M of cash and equivalents.
Open the full interactive Innoviva financials → Quarterly statements, key ratios, valuation history and price charts.
Innoviva Key Stats
| Share Price | $20.74 |
|---|---|
| Market Cap | $1.52B |
| P/E Ratio | 6.3 |
| Revenue YoY Growth | +14.7% |
| 52-Week Range | $16.67 – $24.24 |
| Shares Outstanding | 73.4 million (basic, 2026 Q2) |
Innoviva Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $336.8M | $391.9M | $331.3M | $310.5M | $358.7M | $411.3M |
| Cost of Goods Sold | — | — | $44.4M | $116.4M | $321.3M | $77.4M |
| Gross Profit | — | — | $286.9M | $194.1M | $37.4M | $307.7M |
| Operating Income | $321.1M | $375.1M | $182.0M | $61.9M | -$176.2M | $163.7M |
| Pre-Tax Income | $354.2M | $445.3M | $286.9M | $194.1M | $37.4M | $326.9M |
| Income Tax | $60.4M | $76.4M | $66.7M | $14.4M | $14.0M | $55.7M |
| Net Income | $224.4M | $265.9M | $213.9M | $179.7M | $23.4M | $271.2M |
| Diluted EPS | $2.02 | $2.87 | $2.37 | $2.20 | $0.36 | $3.30 |
Innoviva Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $107.8M | $114.6M | $98.0M | $119.6M |
| Net Income | $89.9M | $164.2M | $186.6M | -$83.4M |
| Diluted EPS | $1.08 | $1.94 | $2.22 | -$1.14 |
Innoviva Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $246.5M | $201.5M | $291.0M | $193.5M | $305.0M | $550.9M |
| Current Assets | $342.1M | $313.7M | $443.5M | $344.2M | $554.3M | $727.5M |
| Total Assets | $999.6M | $926.4M | $1.23B | $1.24B | $1.30B | $1.64B |
| Current Liabilities | $6.1M | $5.8M | $135.0M | $38.1M | $236.1M | $49.7M |
| Total Long-Term Debt | $385.5M | $394.7M | $444.2M | $446.2M | $256.3M | $257.7M |
| Total Liabilities | $459.7M | $511.7M | $665.7M | $568.6M | $609.9M | $462.3M |
| Shareholders' Equity | $539.9M | $414.7M | $565.8M | $675.0M | $691.2M | $1.17B |
Innoviva Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $313.1M | $363.8M | $201.7M | $141.1M | $188.7M | $196.9M |
| Cash From Investing | -$314.9M | $43.7M | -$56.6M | -$66.8M | -$63.8M | $40.5M |
| Cash From Financing | -$29.8M | -$452.5M | -$55.6M | -$171.8M | -$13.5M | $8.6M |
| Free Cash Flow | $313.1M | $363.8M | $201.7M | $140.7M | $188.4M | $195.8M |
Figures from Innoviva's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Innoviva financials page for every line item.
Innoviva Company Profile
| Ticker | INVA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Burlingame, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001080014 |
Frequently Asked Questions
What was Innoviva's revenue in fiscal 2025?
Innoviva (INVA) reported revenue of $411.3M for fiscal 2025.
What is Innoviva's annual revenue history?
Innoviva's annual revenue by fiscal year: 2020: $336.8M; 2021: $391.9M; 2022: $331.3M; 2023: $310.5M; 2024: $358.7M; 2025: $411.3M.
What was Innoviva's net income in fiscal 2025?
Innoviva reported net income of $271.2M for fiscal 2025.
What was Innoviva's earnings per share (EPS) in fiscal 2025?
Innoviva's diluted EPS was $3.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Innoviva generate in fiscal 2025?
Innoviva generated $195.8M of free cash flow in fiscal 2025.
What was Innoviva's revenue last quarter?
In its most recent reported quarter (2026 Q2), Innoviva reported revenue of $119.6M.
How much debt does Innoviva have?
Innoviva reported $257.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Innoviva are outstanding?
Innoviva reported a weighted average of 73.4 million basic shares outstanding in 2026 Q2.
What is Innoviva's market cap?
Based on its latest closing price, Innoviva (INVA) has a market capitalization of about $1.52B.
When does Innoviva's fiscal year end?
Innoviva's fiscal year end, as registered with the SEC, is December 31.
Where is Innoviva headquartered?
Innoviva lists its business address in Burlingame, California in its SEC filings.